Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 24 clinical trials
PI Vs. NNRTI Based Therapy for HIV Advanced Disease

Ritonavir boosted protease inhibitor based therapy will have equivalent antiviral efficacy over 48 weeks compared to NNRTI based therapy in patients who are antiretroviral therapy naïve

ritonavir
zidovudine
lopinavir/ritonavir
antiretroviral agents
lamivudine
  • 32 views
  • 07 Nov, 2020
  • 5 locations
The Potential of Oral Camostat in Early COVID-19 Disease in an Ambulatory Setting to Reduce Viral Load and Disease Burden

study is to assess whether Camostat, a serine protease inhibitor available in an oral formulation has the potential to be studied as an antiviral drug in a large scale ambulatory setting to prevent

  • 0 views
  • 26 Jan, 2021
  • 1 location
Pilot Study of Raltegravir Lipodystrophy IISP

The substitution of raltegravir for the NRTIs will result in some reversal of the long term adverse effect of lipodystrophy (specifically peripheral lipoatrophy) that is associated with the chronic use of NRTIs. Changing the HAART regimen in patients with a sustained virological response from a PI plus NRTI to a …

haart
lipodystrophy
raltegravir
  • 34 views
  • 08 Nov, 2020
  • 1 location
Second-line Switch to Dolutegravir Study

). Second line regimens are composed of 2 NRTI plus a ritonavir boosted protease inhibitor(PIr). This is based on evidence showing good clinical outcomes on this regimen. PIr are associated with side

  • 9 views
  • 24 Jan, 2021
  • 4 locations
The Impact of Camostat Mesilate on COVID-19 Infection

. Camostat Mesilate is a potent serine protease inhibitor. Utilizing research on severe acute respiratory syndrome coronavirus (SARS-CoV) and the closely related SARS-CoV-2 cell entry mechanism, it has been

SARS
cough
angiotensin converting enzyme
dyspnea
covid-19
  • 34 views
  • 24 Dec, 2020
  • 14 locations
The Late Presenter Treatment Optimisation Study

HIV: The Boosted Protease Inhibitor combination (PI) which is a combination tablet containing: darunavir, cobicistat, emtricitabine and tenofovir alafenamide. It was approved for use in Europe

tenofovir
protease
hiv viral load
opportunistic infection
integrase inhibitors
  • 120 views
  • 23 Jan, 2021
  • 29 locations
High Dose Ritonavir/Lopinavir Liquid Formulation in Salvage Therapy for Protease Inhibitor Resistant HIV Disease

The purpose of this study is to evaluate the safety, tolerability and efficacy of higher doses of lopinavir/ritonavir, in combination with other anti-HIV medications when administered as either the capsule or liquid formulations, among patients who have not had full viral suppression despite treatment with 3 classes of HIV medications, …

ritonavir
kaletra
lopinavir/ritonavir
AIDS
HIV Infection
  • 9 views
  • 07 Nov, 2020
  • 1 location
Switching From Protease Inhibitor/Ritonavir to Generic Single Tablet Regimen of Tenofovir Alafenamide/Emtricitibine/Dolutegravir

This is a phase III, multicenter, open-label, single-arm study of 190 virologically suppressed HIV-infected adults

ritonavir
tenofovir
protease
HIV Vaccine
integrase inhibitors
  • 0 views
  • 25 Jan, 2021
  • 2 locations
Efficacy of Ulinastatin for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients

This is a phase 3, open-label, multicenter, randomized controlled phase III clinical trial. The purpose of this study is to evaluate the efficacy of ulinastatin, a kind of protease inhibitor, in

  • 19 views
  • 24 Jan, 2021
  • 1 location
Rituximab in Patients With Relapsed or Refractory TTP-HUS

the ADAMTS13 protease inhibitor. Patients with TTP-HUS not responding to standard therapy or patients with relapsed disease may have particular benefit. Treatments that decrease the

  • 54 views
  • 07 Nov, 2020
  • 8 locations